Mr. David Preiner reports

MEDIVOLVE ANNOUNCES LAUNCH OF NORMAL COURSE ISSUER BID

Medivolve Inc. intends to commence a normal course issuer bid (NCIB) to buy back common shares of the company through the facilities of NEO Exchange Inc. and/or other Canadian alternative trading platforms. The actual number of common shares that may be purchased under the NCIB and the exact timing of such purchases will be determined by the company.

The company is undertaking the NCIB because its management believes that, currently, and from time to time, the market price of its common shares may not reflect the underlying value of the company's business and prospects. Management believes that, at such times, the purchase of common shares for cancellation would be in the best interests of the company's shareholders and an appropriate use of its cash on hand.

The NCIB has been approved by the company's board of directors and accepted by the exchange and will be executed in accordance with the applicable rules and policies of the exchange and any applicable Canadian securities laws. The NCIB shall commence on May 5, 2022, and run through May 3, 2023, or on such earlier date as the NCIB is complete.

Under the terms of the NCIB, the company may, if considered advisable, purchase its common shares in open market transactions through the facilities of the exchange and/or other Canadian alternative trading platforms not to exceed up to 10 per cent of the public float for the common shares as of May 3, 2022, or 38,449,060 common shares, purchased in aggregate. The price that the company will pay for the common shares shall be the prevailing market price at the time of purchase and all purchased common shares will be cancelled by the company. In accordance with exchange rules, daily purchases (other than pursuant to a block purchase exception) on the exchange under the NCIB cannot exceed 25 per cent of the average daily trading volume on the exchange as measured from Nov. 3, 2021, to May 3, 2022. The company has appointed PI Financial Corp. to co-ordinate and facilitate purchases under the NCIB.

About Medivolve Inc.

Medivolve is a health care technology company that seeks to reinvent the U.S. health care system by leveraging a bespoke telehealth platform, a clinical diagnostic network and a data-driven artificial intelligence framework to improve patient care. The company was born out of the health care crisis, to rethink, relearn and ultimately reimagine a better way for the health care system to operate. Its network of retail collection sites plays an essential role in recovery by giving all Americans access to fast, accurate and inexpensive clinical services when and where they need them. These centres will also play a pivotal role in diagnostic testing, vaccinations and other point-of-care services. The company is building disruptive technologies to make it easier and faster to identify, treat and prevent medical issues. In doing so, it is working to give patients a holistic and empowered view of their personal health. The company's long-term mission is to permanently fix systemic issues in the nation's fragmented, overly complex and expensive health care system. Medivolve's next growth phase is about pivoting the model and putting the pieces together to build a profitable, software-as-a-service-based (SaaS) health tech company. Medivolve brings data-driven clinical diagnostics, physician recommendations and prescription medications directly to people, all powered by a singular, streamlined technology network. A powerful, singular purpose unites the company's team: harnessing the transformative power of technology to create healthier lives. Underpinned by a bespoke, AI-driven (artificial intelligence) platform, the company is developing a stealth system that constantly gets smarter, takes the guesswork out of diagnostics and flags critical health issues immediately to deliver an unparalleled level of personalization for each patient. It is determined to push the boundaries of what is possible -- not just for its business and its shareholders, but for physicians and patients, and the future of health care. The company strives to achieve a continuity of care never seen before, a game-changer for its business and patients in the communities the company serves.

We seek Safe Harbor.